• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Sanofi CEO Paul Hudson says his company is the Big Pharma 'least exposed' to...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 28, 2022 at 12:32: PM
via Among its Big Pharma peers, Sanofi is the pharma stock “least exposed” to generic competition through 2030, CEO Paul Hudson said on an investor call Thursday. That’s because Aubagio’s plunge off the patent cliff in 2023 marks Sanofi’s “last meaningful [loss of exclusivity] this decade,” the helmsman explained. Further, Sanofi expects the continued momentum behind Dupixent to more than make up for its Aubagio sales slide, Hudson said.

article source
 

<



Similar threads

cafead
More program cuts ahead as Sanofi CEO Paul Hudson continues to reshape the company
Replies
0
Views
154
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
A year into Sanofi&#039;s revamp, CEO Paul Hudson collects €11.34M in 2020 pay—including...
Replies
0
Views
255
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi Slims Top Executive Ranks as New CEO Paul Hudson Revamps Strategy
Replies
0
Views
214
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Stop and plan it out: Sanofi CEO Paul Hudson offers up advice for digitally ambitious pharmas
Replies
0
Views
253
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
New Sanofi CEO Paul Hudson embarks on fact-finding journey. What&#039;s his next move?
Replies
0
Views
314
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote